Clinical Trial Update: A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on PM8002 (anti-PD-L1/VEGF) in combination with chemotherapy for non-small cell lung cancer, currently active but not recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PM8002

Snippet

Sponsor: Biotheus Inc. | Conditions: NSCLC | Phase 2 | Status: ACTIVE_NOT_RECRUITING